Therapeutic responses of non-small cell lung cancer (NSCLC) to epidermal growth factor
receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are known to be associated with EGFR …

Introduction: With increasing life expectancy over the last several decades, the incidence of
lung cancer is increasing in the elderly population too. In clinical practice about 50% of lung …

Background Surgery combined with chemotherapy is an important therapy for non-small cell
lung cancer (NSCLC). However, chemotherapy drug resistance seriously hinders the …

Survivin is an anti-apoptotic protein that is implicated in the regulation of apoptosis and cell
cycle in various types of cancers. The current study explored the effect of survivin gene …

Abstract Introduction The osimertinib (AZD9291) US Expanded Access Program (EAP)
provided compassionate access to osimertinib prior to US Food and Drug Administration …

Background: Epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase
(ALK) tyrosine kinase inhibitors (TKIs) can cause intolerable adverse events in patients with …

Introduction: Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related
deaths in the USA and worldwide. At diagnosis, half of the patients are over 70 years of age …

Circadian rhythms may influence the pharmacokinetics of drugs. This study aimed to
investigate the pharmacokinetic characteristics of gefitinib at different dosing times and the …

Zytostatika sind wichtige Bausteine für die Krebstherapie. Veränderte Organfunktionen,
Komorbiditäten und Begleitmedikationen beeinflussen das Toxizitätsprofil von Zytostatika …